Hu-8F4

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHu-8F4
Drug Alias Nameanti-PR1/HLA-A2 monoclonal antibody (MD Anderson Cancer Center)h8F4Hu-8F4
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsImmunostimulantsHuman leukocyte antigen modulators
TargetsHuman leukocyte antigen
Therapy Area/IndicationsPrimary MyelofibrosisMyelodysplastic SyndromesHematologic Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesAstellas Pharma IncThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsPrimary MyelofibrosisMyelodysplastic SyndromesHematologic Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A